These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36796874)

  • 1. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.
    Khanna D; Maher TM; Volkmann ER; Allanore Y; Smith V; Assassi S; Kreuter M; Hoffmann-Vold AM; Kuwana M; Stock C; Alves M; Sambevski S; Denton CP
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36796874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
    Assassi S; Tumuluri S; Levin RW
    Clin Exp Rheumatol; 2023 Aug; 41(8):1713-1719. PubMed ID: 37534955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.
    Denton CP; Goh NS; Humphries SM; Maher TM; Spiera R; Devaraj A; Ho L; Stock C; Erhardt E; Alves M; Wells AU
    Rheumatology (Oxford); 2023 May; 62(5):1870-1876. PubMed ID: 36111858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
    Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
    Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Avouac J; Hoffmann-Vold AM; Smith V; Toenges G; Alves M; Distler O
    RMD Open; 2024 Sep; 10(3):. PubMed ID: 39242112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
    Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
    Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
    Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
    Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
    Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
    Volkmann ER; Kreuter M; Hoffmann-Vold AM; Wijsenbeek M; Smith V; Khanna D; Denton CP; Wuyts WA; Miede C; Alves M; Sambevski S; Allanore Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4397-4408. PubMed ID: 35150246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
    Allanore Y; Vonk MC; Distler O; Azuma A; Mayes MD; Gahlemann M; James A; Kohlbrenner V; Alves M; Khanna D; Highland KB;
    Ann Rheum Dis; 2022 Dec; 81(12):1722-1729. PubMed ID: 35973804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
    Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
    Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
    Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
    Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
    Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
    Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.